Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP453939.RAiZbfkjLPjVLM_COUqbkbPeJI-1psKg-gK5u0q3r--Uw130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP453939.RAiZbfkjLPjVLM_COUqbkbPeJI-1psKg-gK5u0q3r--Uw130_assertion type Assertion NP453939.RAiZbfkjLPjVLM_COUqbkbPeJI-1psKg-gK5u0q3r--Uw130_head.
- NP453939.RAiZbfkjLPjVLM_COUqbkbPeJI-1psKg-gK5u0q3r--Uw130_assertion description "[On multivariate analysis, TA2 adenomas were more likely to have a KRAS mutation [odds ratio (OR) 6.6, 95% confidence interval (CI), 3.0-14.2], MGMT loss (OR 6.2, 95% CI, 2.4-16.0), or p53 overexpression (OR 5.6, 95% CI, 2.3-13.7) than TA1.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP453939.RAiZbfkjLPjVLM_COUqbkbPeJI-1psKg-gK5u0q3r--Uw130_provenance.
- NP453939.RAiZbfkjLPjVLM_COUqbkbPeJI-1psKg-gK5u0q3r--Uw130_assertion evidence source_evidence_literature NP453939.RAiZbfkjLPjVLM_COUqbkbPeJI-1psKg-gK5u0q3r--Uw130_provenance.
- NP453939.RAiZbfkjLPjVLM_COUqbkbPeJI-1psKg-gK5u0q3r--Uw130_assertion SIO_000772 21263241 NP453939.RAiZbfkjLPjVLM_COUqbkbPeJI-1psKg-gK5u0q3r--Uw130_provenance.
- NP453939.RAiZbfkjLPjVLM_COUqbkbPeJI-1psKg-gK5u0q3r--Uw130_assertion wasDerivedFrom befree-20140225 NP453939.RAiZbfkjLPjVLM_COUqbkbPeJI-1psKg-gK5u0q3r--Uw130_provenance.
- NP453939.RAiZbfkjLPjVLM_COUqbkbPeJI-1psKg-gK5u0q3r--Uw130_assertion wasGeneratedBy ECO_0000203 NP453939.RAiZbfkjLPjVLM_COUqbkbPeJI-1psKg-gK5u0q3r--Uw130_provenance.